Announcements
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
- Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
- Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
- Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
- Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
- Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
More ▼
Key statistics
On Thursday, Eledon Pharmaceuticals Inc (2TK:DEU) closed at 1.90, -28.03% below its 52-week high of 2.64, set on May 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.85 |
---|---|
High | 1.93 |
Low | 1.85 |
Bid | 1.92 |
Offer | 1.95 |
Previous close | 1.98 |
Average volume | 1.12k |
---|---|
Shares outstanding | 24.20m |
Free float | 22.85m |
P/E (TTM) | -- |
Market cap | 51.54m USD |
EPS (TTM) | -5.59 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 19:46 BST.
More ▼